Lifecore Biomedical, Inc. (LFCR)
(Delayed Data from NSDQ)
$4.85 USD
-0.24 (-4.72%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $4.85 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Cash flow Statements
Fiscal Year End for Lifecore Biomedical, Inc falls in the month of May.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
5/31/2024 | 5/31/2023 | 5/31/2022 | 5/31/2021 | 5/31/2020 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -99.56 | -97.43 | -32.67 | -38.19 |
Depreciation/Amortization & Depletion | NA | 14.59 | 78.68 | 19.87 | 18.84 |
Net Change from Assets/Liabilities | NA | 20.03 | -6.60 | 8.89 | -27.66 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 47.51 | 0.96 | 18.93 | 29.97 |
Net Cash From Operating Activities | NA | -17.44 | -24.40 | 15.02 | -17.04 |
Property & Equipment | NA | -21.48 | -26.99 | -10.86 | -24.25 |
Acquisition/ Disposition of Subsidiaries | NA | 16.67 | 73.50 | 0.00 | 0.00 |
Investments | NA | 0.00 | 45.10 | 0.00 | 0.00 |
Other Investing Activities | NA | 0.00 | -9.84 | 0.00 | 0.36 |
Net Cash from Investing Activities | NA | -4.81 | 81.77 | -10.86 | -23.89 |
Uses of Funds
5/31/2024 | 5/31/2023 | 5/31/2022 | 5/31/2021 | 5/31/2020 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 42.90 | 0.00 | 0.00 | 0.03 |
Issuance (Repayment) of Debt | NA | 26.31 | -66.41 | 55.87 | 16.38 |
Increase (Decrease) Short-Term Debt | NA | -23.19 | 11.00 | -48.40 | 25.40 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -6.32 | -1.61 | -10.89 | -1.79 |
Net Cash from Financing Activities | NA | 39.70 | -57.02 | -3.42 | 40.02 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 17.45 | 0.35 | 0.74 | -0.91 |
Cash at Beginning of Period | NA | 1.64 | 1.30 | 0.55 | 1.47 |
Cash at End of Period | NA | 19.09 | 1.64 | 1.30 | 0.55 |
Diluted Net EPS | NA | -3.32 | -3.31 | -1.12 | -1.31 |
Fiscal Year End for Lifecore Biomedical, Inc falls in the month of May.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
5/31/2024 | 2/29/2024 | 11/30/2023 | 8/31/2023 | 5/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | NA | NA | NA | -99.56 |
Depreciation/Amortization & Depletion | NA | NA | NA | NA | 14.59 |
Net Change from Assets/Liabilities | NA | NA | NA | NA | 20.03 |
Net Cash from Discontinued Operations | NA | NA | NA | NA | 0.00 |
Other Operating Activities | NA | NA | NA | NA | 47.51 |
Net Cash From Operating Activities | NA | NA | NA | NA | -17.44 |
Property & Equipment | NA | NA | NA | NA | -21.48 |
Acquisition/ Disposition of Subsidiaries | NA | NA | NA | NA | 16.67 |
Investments | NA | NA | NA | NA | 0.00 |
Other Investing Activities | NA | NA | NA | NA | 0.00 |
Net Cash from Investing Activities | NA | NA | NA | NA | -4.81 |
Uses of Funds
5/31/2024 | 2/29/2024 | 11/30/2023 | 8/31/2023 | 5/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | NA | NA | NA | 42.90 |
Issuance (Repayment) of Debt | NA | NA | NA | NA | 26.31 |
Increase (Decrease) Short-Term Debt | NA | NA | NA | NA | -23.19 |
Payment of Dividends & Other Distributions | NA | NA | NA | NA | 0.00 |
Other Financing Activities | NA | NA | NA | NA | -6.32 |
Net Cash from Financing Activities | NA | NA | NA | NA | 39.70 |
Effect of Exchange Rate Changes | NA | NA | NA | NA | 0.00 |
Net Change In Cash & Equivalents | NA | NA | NA | NA | 17.45 |
Cash at Beginning of Period | NA | NA | NA | NA | 1.64 |
Cash at End of Period | NA | NA | NA | NA | 19.09 |
Diluted Net EPS | NA | NA | NA | NA | -1.16 |